WILLIAM J. LINK PHD - 24 Jun 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Director
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 24 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2024, 18:25:30 UTC
Previous filing: 14 Jun 2024
Next filing: 14 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+3,350	+2.5%		139,982	24 Jun 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Restricted Stock Units	Options Exercise	$0	-3,350	-100%	$0.000000^*	0	24 Jun 2024	Common Stock	3,350		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2	Each RSU represents a contingent right to receive one share of the Company's common stock.
F3	RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.